Danish Pharma Stock News

As European markets experience modest gains, driven by optimism around geopolitical developments and economic growth, investors are increasingly focused on identifying promising opportunities within the region. In this environment, growth companies with significant insider ownership can be particularly appealing as they often signal confidence from those closest to the business.

Why UIE (CPSE:UIE) Is Back on Investors’ Radar UIE (CPSE:UIE) just wrapped up a busy Annual General Meeting, combining a new final dividend, changes to its memorandum and Articles of Association, and a fresh board appointment with first quarter results showing higher sales and a net loss. See our latest analysis for UIE. Those AGM decisions and the first quarter update come as UIE’s share price, now at DKK363.0, has slipped around 6% over the past month but still shows a 1-year total...

Rockwool (CPSE:ROCK B) has just completed a capital reduction that follows a multi year share buyback and recent first quarter earnings. This puts the focus squarely on how a smaller share base meets weaker profitability. See our latest analysis for Rockwool. Rockwool’s 1 day share price return of 2.64% and 1 month share price return of 10.30% suggest short term momentum has picked up following the capital reduction and the Q1 loss, even though the year to date share price return is down...

Last week saw the newest second-quarter earnings release from Per Aarsleff Holding A/S ( CPH:PAAL B ), an important...

ISS stock moves without a clear catalyst ISS (CPSE:ISS) shares have been active recently, with the stock up about 14% over the past month and 17% over the past 3 months, prompting investors to reassess what is currently priced in. See our latest analysis for ISS. At a current share price of DKK263.8, ISS has delivered a 22.36% year to date share price return and a 51.43% total shareholder return over the past year, suggesting recent momentum. If ISS has caught your attention, it can help to...

Recent share performance and business profile Novo Nordisk (CPSE:NOVO B) has drawn investor attention after a recent rise in its share price, with the stock up 1.2% on the day and posting gains over the past week and month. At a last close of DKK 293.60 and a market value of about DKK 1.30b, the company operates at the center of the global diabetes and obesity treatment market, alongside its rare disease franchise. See our latest analysis for Novo Nordisk. Recent gains, including a 23.41% 90...

PARKEN Sport & Entertainment (CPSE:PARKEN) has opened 2026 with Q1 revenue of DKK 431.3 million and a net income loss of DKK 20.2 million, setting a more mixed tone after a profitable trailing 12 month period. The company has seen quarterly revenue move from DKK 254.3 million in Q1 2025 to DKK 431.3 million in Q1 2026, alongside basic EPS that has swung between a loss of DKK 5.90 in Q1 2025 and a profit of DKK 9.57 in Q4 2025, leaving investors focused on how resilient margins look after the...

Per Aarsleff Holding (CPSE:PAAL B) has just posted its Q2 2026 numbers, with revenue of DKK6.1b and basic EPS of DKK10.22, while the trailing twelve months show total revenue of DKK24.1b and basic EPS of DKK48.20. Over recent quarters, revenue has ranged from DKK5.3b in Q2 2025 to DKK6.2b in Q1 2026, with quarterly EPS moving between DKK8.84 and DKK16.36 over the same period. This results snapshot sits on a 3.8% net margin that investors may focus on as they weigh the balance of growth and...

GN Store Nord (CPSE:GN) has drawn fresh attention after BlueParrott, part of the group, introduced its Pro Series Bluetooth headsets for long haul truck drivers, pairing AI powered voice isolation with active noise cancellation. See our latest analysis for GN Store Nord. The launch of the BlueParrott Pro Series comes as GN Store Nord’s share price sits at DKK97.52, with a 7 day share price return of 3.63% but a year to date share price decline of 11.26%. The 5 year total shareholder return is...

Novo Nordisk (CPSE:NOVO B) presented new POSEIDON study data on cardiovascular inflammation at a major scientific congress. The study found that many patients with atherosclerotic cardiovascular disease, chronic kidney disease, or heart failure have persistent cardiovascular inflammation despite guideline recommended care. These real world findings highlight a significant unmet medical need and may influence future approaches to cardiovascular risk reduction. Novo Nordisk, traded as...

H. Lundbeck (CPSE:HLUN B) is back on investors’ radar after South Korea’s Ministry of Food and Drug Safety granted marketing authorization for eptinezumab, its intravenous anti-CGRP preventive migraine treatment for adults. See our latest analysis for H. Lundbeck. The eptinezumab approval lands at a time when Lundbeck’s DKK42.84 share price has a 90 day share price return of 11.62%, while the 1 year total shareholder return of 21.57% points to momentum that has built over a longer period...

Royal Unibrew stock performance and recent valuation context Royal Unibrew (CPSE:RBREW) has caught investor attention after a period of weaker share performance, with the stock down about 36% over the past 3 months and roughly 27% year to date. See our latest analysis for Royal Unibrew. At a share price of DKK411.0, Royal Unibrew’s recent slide is clearer in context, with the 90 day share price return down 35.73% and the 1 year total shareholder return down 21.71%, pointing to fading momentum...

Amid a backdrop of rising hopes for geopolitical de-escalation and positive market momentum, the pan-European STOXX Europe 600 Index has climbed 3.00% recently, reflecting a broader optimism in European markets. As investors navigate these dynamic conditions, identifying promising small-cap stocks can be crucial; such stocks often exhibit strong fundamentals and growth potential that align with prevailing economic trends.

Genmab (CPSE:GMAB) is drawing fresh attention after announcing 23 abstracts for the 2026 ASCO and EHA meetings, largely centered on epcoritamab and other late stage oncology candidates in ongoing clinical trials. See our latest analysis for Genmab. Genmab's latest ASCO and EHA abstracts come after a mixed price pattern, with the share price up 3.62% over the past week but down 14.45% year to date. The 1 year total shareholder return of 23.17% contrasts with weaker 3 and 5 year total...

NKT (CPSE:NKT) is back in focus after reporting first quarter 2026 earnings, with sales of €864 million and net income of €61 million, alongside reaffirmed full year revenue guidance. See our latest analysis for NKT. At a share price of DKK1,106.0, NKT has delivered a 22.55% 30 day share price return and a 96.45% 1 year total shareholder return. If you are looking for other power and grid related opportunities after NKT's latest earnings, this could be a good moment to scan 35 power grid...

Carlsberg Baltics recently announced that long-serving regional head Rolandas Viršilas, who has led its Baltic operations for over 20 years, stepped down from his role on May 26, 2026, with Lukasz Chalaczkiewicz assuming leadership from May 27, 2026. This leadership transition brings in a new regional head with extensive FMCG experience across Central and Eastern Europe, potentially influencing how Carlsberg executes its growth and operational plans in Estonia, Latvia, and Lithuania. We’ll...

Demant (CPSE:DEMANT) has drawn investor attention after CEO Søren Nielsen warned that upcoming EU AI rules could create overlapping medical device regulations, potentially affecting approval timelines and competitiveness for European hearing healthcare companies. See our latest analysis for Demant. That warning comes as Demant’s share price has moved sharply higher in the short term, with a 1 month share price return of 20.47% and 3 month share price return of 38.33%. This contrasts with a 1...

Readers hoping to buy TORM plc ( CPH:TRMD A ) for its dividend will need to make their move shortly, as the stock is...

It's been a good week for TCM Group A/S ( CPH:TCM ) shareholders, because the company has just released its latest...

Bavarian Nordic (CPSE:BAVA) received a major contract extension from the US government’s BARDA for its JYNNEOS smallpox vaccine. The extension secures remaining JYNNEOS doses and includes an additional US$97 million commitment for further vaccine supply. The agreement supports a shift to a freeze dried formulation designed for longer shelf life and stockpile use. The company has updated its 2026 revenue and business guidance following the new BARDA commitments. For investors looking at...

Investors may be wondering whether Vestas Wind Systems, at a recent price of DKK194.60, still offers value or if most of the opportunity is already priced in. The stock has returned 1.9% over the last 7 days, 1.6% over the last 30 days, 8.9% year to date, and 92.8% over the past year. Returns over the past 3 and 5 years show declines of 1.8% and 17.5% respectively. Recent headlines around Vestas Wind Systems have focused on the company as a key listed player in the global wind sector. This...

We wouldn't blame TORM plc ( CPH:TRMD A ) shareholders if they were a little worried about the fact that Jacob...

Shareholders appeared unconcerned with Coloplast A/S' ( CPH:COLO B ) lackluster earnings report last week. Our analysis...

Recent performance snapshot for A.P. Møller Mærsk (CPSE:MAERSK B) A.P. Møller Mærsk (CPSE:MAERSK B) has seen mixed share performance recently, with the stock up 0.5% on the day and 4.8% over the past week, but down 3.3% over the past month. See our latest analysis for A.P. Møller - Mærsk. Looking beyond the recent pullback over the past month, the share price is roughly flat year to date while the 1 year total shareholder return of 18.8% points to stronger longer term momentum. If you are...